
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a commercial-stage biopharmaceutical company that is well-positioned for potential success with its diverse portfolio of drug candidates, including VTAMA and Batoclimab, in different stages of development. With a positive outlook on its clinical data and potential approvals, the company's valuation is expected to increase based on its revenue estimates. However, as with any biopharmaceutical company, there are regulatory and commercial risks that could impact the achievement of its price target, as well as technical risks related to the validation of its technology. Nonetheless, Roivant Sciences has demonstrated a strong track record of success in its clinical trials and has a promising pipeline with blockbuster potential. With its well-capitalized position and multiple upcoming catalysts, the company is on track to achieve profitability and potentially acquire or in-license additional assets. Overall, the company's focus on combination therapies and its positioning within the pulmonary hypertension landscape bode well for its future success in the biopharmaceutical industry.
Bears say
Roivant Sciences is facing challenges in diversifying its drug pipeline beyond its current commercial stage treatment, tapinarof. While the company has promising drug candidates in development for various indications such as plaque psoriasis, dermatomyositis, and non-infectious uveitis, their timeline for potential launches and potential efficacy compared to other candidates may not be competitive. Additionally, their pricing strategy for IMVT-1402 may face scrutiny from payers and may not be sustainable in the long term.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares